Warning: Constant WP_TEMP_DIR already defined in /home/fredeln118/domains/vital-imi.eu/public_html/wp-config.php on line 74 Preventing Infectious Diseases for Healthy Ageing: The VITAL Public-Private Partnership Project – Vital-Imi
Preventing Infectious Diseases for Healthy Ageing: The VITAL Public-Private Partnership Project
Prevention of infectious diseases through immunisation of the growing ageing adult population is essential to improve healthy ageing. However, many licenced and recommended vaccines for this age group show signs of waning of the protective effect due to declining immune responses (immuno-senescence) and decreasing vaccine uptake. Today’s major challenge is to improve vaccine effectiveness and uptake and to deploy efficient vaccination strategies for this age group. The Vaccines and InfecTious diseases in the Ageing popuLation (VITAL) project, with partners from 17 academic & research groups and public institutes as well as seven industry collaborators, aims to address this challenge. The ambition is to provide evidence-based knowledge to local decision makers. Using a holistic and multidisciplinary approach and novel analytical methods, VITAL will provide tools that allow the development of targeted immunisation programs for ageing adults in European countries. The project is based on four pillars focussing on the assessment of the burden of vaccine-preventable diseases in ageing adults, the dissection of the mechanisms underlying immuno-senescence, the analysis of the clinical and economic public health impact of vaccination strategies and the development of educational resources for healthcare professionals. By the end of the project, a clear, detailed, and integrated program should be available for implementing a consistent, affordable, and sustainable vaccination strategy for ageing adults with regular evaluations of its impact over time.
Debbie van Baarle: Center for Infectious Disease Prevention, National Institute for Public Health and the Environment, Bilthoven, the Netherlands & Center for Translational Immunology, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands
Kaatje Bollaerts: P-95, Heverlee, Belgium
Giuseppe Del Giudice: GSK, Siena, Italy
Stephen Lockhart: Pfizer, Hurley, United Kingdom
Christine Luxemburger: Sanofi Pasteur, Lyon, France
Maarten J. Postma: Rijksuniversiteit Groningen, Groningen, the Netherlands
Aura Timen: Center for Infectious Disease Prevention, National Institute for Public Health and the Environment, Bilthoven, the Netherlands
Baudouin Standaert: GSK, Wavre, Belgium
Published: Vaccine, July 24th, 2020
Keywords: Elderly, Immuno-senescence, Infectious diseases, Public health, Public-private partnership, Vaccine
You can contact us by using the contact form here.
The VITAL project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806776. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.